Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide

NCT03005366 is registered in ClinicalTrials.gov with David Filgueiras-Rama as lead sponsor.

NCT NCT03005366
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03005366 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Clinical Trial to Study Pharmacological Cardioversion of Paroxysmal Atrial Fibrillation by Vernakalant and Flecainide
Lead sponsor
David Filgueiras-Rama
Phase
Phase 4
Overall status
Completed
Start date
January 31, 2017
Completion date
August 31, 2023
Enrollment
50 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

paroxysmal atrial fibrillation